Unprotected left main coronary artery stenting: immediate and medium- term outcomes of 140 elective procedures  by Silvestri, Marc et al.
Interventional Cardiology
Unprotected Left Main Coronary
Artery Stenting: Immediate and Medium-
Term Outcomes of 140 Elective Procedures
Marc Silvestri, MD, Paul Barragan, MD, Joe¨l Sainsous, MD, Gilles Bayet, MD,
Jean-Baptiste Simeoni, MD, Pierre-Olivier Roquebert, MD, Gilles Macaluso, MD, Jean-Louis Bouvier, MD,
Bertrand Comet, MD
Marseille, France
OBJECTIVES We sought to evaluate immediate and late outcomes after stenting for left main coronary
artery (LMCA) stenosis.
BACKGROUND Conventional percutaneous transluminal coronary angioplasty (PTCA), for which coronary
artery bypass grafting (CABG) has been the gold standard therapy for years, has yielded poor
results in unprotected LMCA lesions. The development of coronary stents, together with
their dramatic patency improvement provided by new antiplatelet regimens and their
validation against restenosis, warrants a reappraisal of angioplasty in LMCA stenosis.
METHODS From January 1993 to September 1998, 140 consecutive unselected patients with unprotected
LMCA stenosis underwent elective stenting. Group I included 47 high-CABG-risk patients,
and group II included 93 low-CABG-risk patients. Ticlopidine without aspirin was routinely
started at least 72 h before the procedure and continued for one month. Patients were
reevaluated monthly. A follow-up angiography was requested after six months.
RESULTS The procedure success rate was 100%. One-month mortality was 9% (4/47) in group I and
0% in group II. A follow-up angiography was obtained in 82% of cases, and target lesion
revascularization was required in 17.4%. One-year actuarial survival was 89% in the first 29
group I patients and 97.5% in the first 63 group II patients.
CONCLUSIONS Stenting of unprotected LMCA stenosis provided excellent immediate results, particularly in
good CABG candidates. Medium-term results were good, with a restenosis rate of 23%,
similar to that seen after stenting at other coronary sites. Stenting deserves to be considered
a safe and effective alternative to CABG in institutions performing large numbers of PTCAs.
(J Am Coll Cardiol 2000;35:1543–50) © 2000 by the American College of Cardiology
In the early days of percutaneous transluminal coronary
angioplasty (PTCA), Andre´as Gruentzig used the proce-
dure to treat unprotected left main coronary artery (LMCA)
stenoses in a few patients (1,2). This practice was promptly
stopped, however, because of its poor results and because of
the publication of several surgical series (3–5) demonstrating
See page 1551
longer survival times after surgical revascularization com-
pared with nonsurgical treatment in patients with LMCA
disease.
Subsequently, a number of interventional cardiology
groups (6–9) also reported disappointing outcomes after
balloon angioplasty alone in LMCA stenosis: there was
substantial perioperative mortality, restenosis rates were
high, and long-term survival rates were unsatisfactory.
Thus, coronary artery surgery remained the gold standard
procedure. However, the explosive growth of coronary
stenting in the 1990s, fueled in part by the dramatic
reduction in thrombotic complications provided by ticlopi-
dine therapy (10–13) and by evidence that stenting reduced
postangioplasty restenosis rates (14,15), prompted new at-
tempts at LMCA dilation, often on a case-by-case basis
(16–19). Since 1993, we offer angioplasty with stenting to
all patients with LMCA stenoses. We have evaluated the
results of this optimized angioplasty procedure.
METHODS
Patients. From January 1993 to November 1998, 8,042
patients were treated at our institution by angioplasty
procedures performed by six operators. Among them, 140
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(1.7%) had a greater than 50% stenosis of an unprotected
(i.e., nonbypassed) LMCA, which was treated by dilation
with implantation of one or more stents. Before the proce-
dure, informed consent was obtained from all these patients
in accordance with the Declaration of Helsinki. Patients
who presented with cardiogenic shock or progressive myo-
cardial infarction (MI) were excluded from the study. Also
excluded were patients who were unable to receive ticlopi-
dine for at least three days before the procedure because of
irregular observance of treatment or severe side effects.
The 140 study patients were divided in two groups.
Group I was composed of the 47 patients categorized as
poor surgical candidates because of a contraindication to
cardiopulmonary bypass by one or more surgeons or of the
presence of any of the following factors: age older than 75
years, history of heart surgery, left ventricular ejection
fraction (LVEF) lower than 35%, renal failure, inadequate
coronary distal runoff or severe respiratory failure. Group II
included the 93 patients with no contraindications to
surgery or factors associated with a decreased likelihood of
successful coronary artery bypass grafting (CABG). Signif-
icant differences were found between the two groups for age,
history of MI or CABG and left ventricular function (Table 1).
Angioplasty procedure. A total of 186 stents were im-
planted in the LMCAs of the 140 patients (mean, 1.33 stent
per artery). The first patients underwent predilation by
inflation for 10 to 15 s of a slightly undersized balloon done
after the stent was prepared on another, semicompliant,
optimally sized balloon to enable immediate stent implan-
tation after the predilation. The stent was delivered by a
short inflation providing a satisfactory balloon profile; mean
pressure used was 12.6 6 2.6 bars (range, 9–20 bars).
Subsequently, we used precrimped stents without predila-
tion whenever the anatomic conditions permitted in order
to avoid the additional period of ischemia. Use of perfusion
balloons was not necessary in any of our patients. Stent
placement was checked by angiography without intravascu-
lar ultrasound (IVUS).
In patients with concomitant lesions of the left anterior
descending (LAD) coronary artery or circumflex artery,
treatment of the LMCA was given priority; however, in
some cases with proximal tortuosity or a risk of impossibility
of pulling back through the stented segment, distal lesions
were treated after LMCA predilation.
Starting on June 1, 1997, distal lesions of the main artery
and lesions of the origin of the LAD and circumflex arteries
were routinely dilated at the end of the procedure using a
double balloon; in some cases, the ostia of the LAD and
circumflex arteries were stented.
Various types of stents were used: the Palmaz-Schatz
stent (Johnson & Johnson Interventional Systems, Roden,
the Netherlands) in 54% of cases (n 5 100); the GFX stent
(Arterial Vascular Engineering, Galway, Ireland) in 28% of
cases, particularly for distal or bifurcation lesions; the
Multilink Duet stent (Advanced Cardiovascular Systems) in
9% of cases; other tubular stents (Saint Coˆme, Biocompat-
ible, Bestent) in 5% of cases; and coil stents (Gianturco-
Roubin I, Cook Corporation, Bloomington, Indiana) in 4%
of cases.
In most patients, the stents were implanted via the
femoral route using a 6F, 7F or 8F guiding catheter (79%,
24% and 5% of cases, respectively). An extra backup catheter
was used in most instances.
Debulking was required before stenting in nine cases
(6%). Neither intraaortic counterpressure balloon support
nor abciximab was used as preventive or curative therapy. In
one of our first patients, preventive cardiopulmonary sup-
port was set up via the femoral route.
Anticoagulation protocol. All 140 patients were treated
using the following protocol:
c Initiation of ticlopidine therapy three days before the
angioplasty procedure, in a dose of 500 mg per day,
without aspirin;
c Intravenous bolus of 7,500 to 10,000 IU of heparin at the
beginning of the procedure;
c Ticlopidine alone, 500 mg/day for one month, without
aspirin or coumadin, followed by aspirin in a dose of
250 mg per day;
c Monitoring in an intensive care unit for 24 h, then in a
cardiology ward room for six days.
Angiography evaluation. Minimal lumen diameter
(MLD) was calculated routinely before dilation and after
stenting, after injection into the artery of 1 mg of molsido-
mide, using the On-line Quantitative Coronary Angiogra-
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CASS 5 Coronary Artery Surgery Study
IVUS 5 intravascular ultrasound
LAD 5 left anterior descending
LMCA 5 left main coronary artery
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
Table 1. Comparison of Group I and Group II Patients
Group I
n 5 47
Group II
n 5 93 p Value
Age 75 6 10 65 6 10 , 0.001
Women 12 (25) 16 (17) NS
Prior MI 17 (36) 8 (9) , 0.005
Prior CABG 11 (23) 0 , 0.005
LVEF (%) 52 6 18 66 6 11 , 0.001
Data are n (%).
CABG 5 coronary artery bypass grafting; LVEF 5 left ventricular ejection
fraction; MI 5 myocardial infarction.
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phy System (DCI, Philips, the Netherlands). The guiding
catheter was used as the calibration reference. A diameter
stenosis of 50% or more was considered significant.
Follow-up. All patients were evaluated monthly by a car-
diologist during the first six months after the angioplasty
procedure. A repeat selective coronary angiogram was re-
quested routinely after six months; if this investigation
proved unfeasible, an exercise test or scintigraphy was
performed.
Statistical analysis. The clinical and angiographic data
were collected prospectively and stored in a computerized
database via computers located in the catheterization labo-
ratory (Summit Medical). Data are reported as means 6
standard deviations. Variables were compared using either
the chi-square test or Fisher exact test. Statistical signifi-
cance was defined as p , 0.05. The confidence intervals for
our rates are 95%. Continuous variables were compared
using variance analysis. The variables that were found to be
significant by univariate analysis were entered into multi-
variate analysis using stepwise logistic regression analysis
with the statistical computer package SPSS (SPSS, Inc.,
Chicago, Illinois). Kaplan Meier survival curves were con-
structed with Log Rank and Wilcoxon test. Statistical
software were SAS and SPSS.
RESULTS
Immediate results. Baseline clinical characteristics of the
140 patients are summarized in Table 2. Mean age was
70.2 6 9 years (range, 36–86); 49% of patients had unstable
angina. In 11% of patients, LMCA disease was diagnosed
upon evaluation for silent ischemia.
Baseline angiographic and procedural data are displayed
in Table 2. Nearly half the patients (47%) had three-vessel
disease. The right coronary artery was occluded in 14% of
patients and showed significant stenosis in 33%. The site of
the LMCA lesion was the ostium in 10% of patients, the
midportion of the artery in 38% and the distal portion in
52%. Mean number of lesions treated per patient was 1.8.
Minimal lumen diameter increased from 1.28 6 0.48 mm
before angioplasty to 3.46 6 0.63 mm after stenting, while
mean diameter stenosis decreased from 73 6 12% to 12 6
8%. The procedural success rate was 100%.
One-month follow-up data. Major cardiac events re-
corded within the first month after the procedure in the two
patient groups are shown in Table 3. In group I (poor
surgical candidates), there were four procedure-related
deaths (9% of group I). Two were sudden deaths that
occurred within the first week and were ascribed to subacute
stent thrombosis, although both events were so abrupt as to
preclude angiography; both patients were in their 80s and
had a poor distal coronary runoff, an LVEF of only 25% and
contraindications to surgery. Another death occurred as a
result of end stage congestive heart failure despite satisfac-
tory revascularization as assessed by angiography. Finally,
one patient died of thrombosis of an aortobifemoral pros-
thesis three weeks after the angioplasty procedure. Other
adverse events in group I consisted of non–Q wave MI in
two patients (4% of group I). None of the group I patients
required bypass grafting or blood transfusion, and none
developed complications at the femoral catheterization site.
In group II (good candidates), the only complication was
a false aneurysm, which was closed by external compression
under ultrasound guidance.
Table 2. Baseline Clinical and Angiographic Characteristics
(140 Study Patients)
Age (yrs) 70.2 6 9
Male gender (%) 79%
Cardiac risk factors (% with the factor)
Hypertension 44%
Diabetes mellitus 14%
Cigarette use 31%
High serum cholesterol 43%
Unstable angina 49%
Recent MI 6%
Silent ischemia 11%
CC4 15%
CC3 13%
CC2 6%
Three-vessel disease 47%
Complete revascularization 70%
RCA
Occlusion 14%
Stenosis 33%
Normal 53%
Pre-PTCA
Mean LMCA stenosis (%) 73 6 12
Mean MLD (mm) 1.28 6 0.48
Ref. diameter (mm) 3.67 6 0.63
Poststenting
Mean LMCA stenosis (%) 12 6 8
Mean MLD (mm) 3.46 6 0.53
Ref. diameter 3.77 6 0.53
CC 5 Canadian classification; LMCA 5 left main coronary artery; MI 5 myocardial
infarction; MLD 5 minimal lumen diameter; PTCA 5 percutaneous transluminal
coronary angioplasty; RCA 5 right coronary artery.
Table 3. One-month Clinical Outcomes (n 5 140 Patients)
Group I
n 5 47
Group II
n 5 93
Total
n 5 140
Death, n (%) 4 (9%) 0 4 (3%)
Subacute thrombosis 2
Terminal left
ventricular failure
1
Aortic prosthesis
thrombosis
1
Nonfatal MI 2 (4%) 0 2 (1%)
CABG 0 0 0
Groin complications 0 1 1 (0.7%)
Blood transfusion 0 0 0
CABG 5 coronary artery bypass grafting; MI 5 myocardial infarction.
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Six-month follow-up data (Table 4). As of this writing,
38 group I patients have been followed up for at least six
months. There was one additional cardiac death in an
82-year-old woman with recurrent angina probably due to
restenosis treated at another institution by pharmacotherapy
without angiographic evaluation. Four group I patients
developed restenosis of the target lesion requiring a repeat
revascularization procedure, which consisted in angioplasty
in three cases and surgery in one.
In Group II, 77 patients had a follow-up of at least six
months. A repeat angiography was done in 82% of these 77
patients. There were two noncardiac deaths (one case each
of cancer and suicide) and one nonfatal MI. Sixteen patients
(16/77, 21%) required repeat revascularization of the
LMCA, which was done by angioplasty in five cases and by
surgery in 11 (11/77, 14%).
The overall repeat revascularization rate in the 115
patients with a follow-up of six months or more was 20/115
(17.4%). Six-month angiography (94 of 115 eligible pa-
tients) showed a 23% restenosis rate defined as more than
50% stenosis. No factors predictive of a need for a repeat
revascularization procedure were identified. In particular,
the site of the lesion on the LMCA had no influence on the
repeat revascularization rate, which was 17% for ostial
lesions, 23% for midportion lesions and 20% for distal
lesions.
One-year follow-up data. One-year data were available for
29 group I patients, of whom 89% were alive and 66% were
alive and free of repeat revascularization procedures (Fig. 1).
In the 63 group II patients followed up for at least one year,
the corresponding figures were 93% and 72% (Fig. 2).
DISCUSSION
Feasibility of LMCA angioplasty and six-month out-
comes. Because it compromises a large proportion of the
myocardium, stenosis of an unprotected LMCA is the most
severe type of coronary artery lesion and carries a high risk
of short-term death in the absence of treatment (20,21).
Interventional revascularization by balloon dilation, atherec-
tomy or laser have provided disappointing results and,
consequently, have been deemed inadvisable in this situa-
tion (8,22–24). The Coronary Artery Surgery Study
(CASS) registry (3), which provides data on a vast patient
population with long follow-ups, has demonstrated un-
equivocally that surgical revascularization improves both
survival and quality of life. However, a number of new
developments have created a need for reappraisal of the role
of interventional treatment in LMCA stenosis. Thus, stent-
ing provides for a reduction in immediate elastic recoil,
Figure 1. Unprotected left main stenting—63 good candidates: one-year event-free survival. CABG 5 coronary artery bypass grafting;
LM 5 left main; PTCA 5 percutaneous transluminal coronary angioplasty.
Table 4. Outcome at Six Months (n 5 115 Patients)
Group I
(n 5 38)
Group II
(n 5 77)
Death 1 (2%) 2 (2.6%)
Cardiac 1 0
No cardiac 0 2 (1 cancer, 1 suicide)
Nonfatal MI 0 1 (0.8%)
TLR 4 (10.5%) 16 (21%)
Repeat LM/PTCA 3 5
CABG 1 11 (14%)
CABG 5 coronary artery bypass grafting; LM/PTCA 5 left main/percutaneous
transluminal coronary angioplasty; MI 5 myocardial infarction; TLR 5 target lesion
revascularization.
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which occurs almost consistently at the LMCA because of
the presence of elastic fibers in the vessel wall (16). Stenting
reduces the risk of procedure-related acute occlusion, which
otherwise would be prohibitive at this anatomic site, and
also decreases the risk of restenosis at other sites (14).
Furthermore, the use of ticlopidine, with or without aspirin,
has substantially decreased the rate of local complications,
particularly of stent thrombosis after one month (10,12,13).
These considerations prompted us to initiate this study in
1993. The first patients included had contraindications to
surgery, were in a critical clinical condition or had extremely
severe anatomic lesions (26 cases). These patients consti-
tuted group I (25). The promising results in these patients,
together with the introduction of further technical improve-
ments, led us to extend our study to good surgical candi-
dates, who constituted group II (26). Our data support the
feasibility of unprotected LMCA stenting because there
were no intraprocedure or immediate postprocedure com-
plications. There were four deaths in group I, including two
sudden deaths within the first week, possibly due to acute
thrombosis. This mortality rate (4/47) can be considered
acceptable given the complex challenges raised by this
high-surgical-risk group (advanced age, multiple lesions on
other vessels, impaired left ventricular function). Further-
more, abciximab was not yet available at the time these
patients were treated. The most striking finding from our
study is, in our opinion, the absence of immediate or
one-month mortality in group II, which is the largest cohort
of good-surgical-risk patients published to date. Stent
thrombosis is a real danger and the major limitation of
LMCA stenting, as it can be responsible for fatal MI. In our
experience, no stent thrombosis was observed in the good
candidate group. Although the patient cohort was not
sufficient to reveal any statistically predictive risk factors, we
believe that the large size of LMCA, optimal deployment of
stents (with kissing balloon inflation for the bifurcation),
perfect compliance with ticlopidine therapy and early de-
tection of patients at high risk of thrombosis (inflammatory
syndromes, cancer, etc.) ensure the lowest possible throm-
bosis rate. Although even a single clinical event could
change the statistical results dramatically given the small
sample size, our data strongly suggest that stenting improves
outcomes after LMCA balloon angioplasty. Indeed, proce-
dural mortality was 9.1% in a study by O’Keefe et al. (6) and
12% in a study by Eldar et al. (7). Our results are consistent
with those reported by Park et al. (18), Wong et al. (27) and
Tamura et al. (28), although in our series good left ventric-
ular function was a selection criterion for group II patients.
Our local complication rate was also very low (0.7%) and
similar to that seen in the general stent-supported angio-
plasty population. This can be ascribed to the use of
ticlopidine and of 6F and 7F catheters. Stenting reduces the
need for hemodynamic assistance (intraaortic counterpres-
sure balloon, circulatory support), which is a well-
established source of local morbidity (29); rapid stent
delivery ensures an optimal result without prolonged isch-
emia.
After six months, there were no cardiac deaths in group II
(good surgical candidates); the only two deaths were due to
cancer and suicide, respectively. At this writing, only 77
group II patients have been followed for more than one year.
However, earlier experience acquired with stenting suggests
Figure 2. Unprotected left main stenting—29 poor candidates: one-year event-free survival. CABG 5 coronary artery bypass grafting;
LM 5 left main; PTCA 5 percutaneous transluminal coronary angioplasty.
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that no cases of subacute thrombosis will occur, because
beyond the first month restenosis is the main complication
and acute events are uncommon. Even in group I, the only
delayed death could have been avoided if a repeat selective
coronary angiogram had been performed to investigate the
recurrent clinical symptoms.
Repeat revascularization procedures. In our series, the
overall rate of repeat revascularization procedures, i.e.,
repeat procedures on the stented LMCA, was 17.4%, a
figure consistent with those reported for other large coro-
nary arteries. Among group II patients with a follow-up of
six months or more, 14% had surgery and 7% had a repeat
angioplasty procedure with a good immediate outcome.
Surgery was recommended to patients with restenosis;
before the angioplasty procedure, patients were told of the
possibility that surgery may subsequently be required. How-
ever, some patients chose to undergo a repeat angioplasty
procedure because of the unpredictable nature of restenosis.
After repeat LMCA angioplasty, 80% of patients remained
free of symptoms, and 20% developed restenosis and were
subsequently operated on. Ninety percent of patients im-
mediately operated on for restenosis were free of symptoms,
and one died after one year. The repeat revascularization
rate was not influenced by the site of the lesion on the
LMCA; thus, the trend toward a higher restenosis rate for
distal lesions, which was found early in our experience, was
not detectable in this larger sample of patients. This is,
without doubt, ascribable in part to technical changes,
particularly to the introduction of simultaneous double
balloon dilation of the LAD and circumflex arteries at the
end of the procedure (30). However, this technique requires
considerable experience on the part of the operator. Also, it
should be borne in mind that the small number of distal
LMCA lesions followed up for six months or more (61/72)
implies the possibility that statistical results may change as
the number of patients increases. No factors significantly
predictive of restenosis were identified by univariate or
multivariate analysis; in particular, diabetes mellitus, final
diameter and inflation pressure had no influence on the
restenosis rate (Table 5).
Multiple and diffuse lesions can often be associated with
LMCA disease. In our work, we attempted 1.7 lesion/
patient and had 11% repeat PTCA on other vessels. One
must take this parameter into consideration in order to
propose the most adequate therapeutic solution to the
patient, which will impel to surgical decision if the number
of lesions is really important.
Selection of the stent according to the lesion. Because
the ostium and trunk of the LMCA contain an abundance
of elastic fibers, we prefer tubular stents and stents that
generate strong radial forces (31). Although it is less often
used now in Europe, the Palmatz-Schatz stent proved
satisfactory for LMCA stenting in our study. Use of coil
stents has been recommended to treat bifurcation lesions.
However, we rarely used coil stents, because they have been
associated with a higher risk of restenosis than tubular stents
(32). Furthermore, the mesh is easily cleared with some of
the currently available tubular stent configurations. Here
again, we advocate double balloon dilation at the end of the
procedure. In France, the use of 6F guide catheters has
proved satisfactory, particularly because of the absence of
occlusion of the ostium and of the low rate of arterial
catheter insertion-site complications.
Debulking before stenting. In our experience, rotational
atherectomy was used in only 6% of cases, the indication
being significant calcifications in the distal LMCA. No
significant influence of this procedure on outcomes was
found, but the number of patients in this subgroup is small.
Debulking can reduce the risk of dissection, facilitate stent
passage and optimize the initial diameter gain (33). How-
ever, it needs to be validated in a larger number of patients,
with special attention to the risk of restenosis.
Ultrasound guidance. We used “simple” angiography
without IVUS to guide stent implantation. Colombo et al.
(34) advocated use of IVUS together with high inflation
pressures, both to reduce the risk of early subacute stent
thrombosis due to inadequate stent deployment and to
decrease the restenosis rate. Our data do not support this
strategy, probably because our patients received preventive
ticlopidine therapy (as did 70% of the patients in the study
by Colombo et al. [34]), a measure that likely contributed to
the absence of subacute thrombosis in our group II patients.
Furthermore, a study by Finet et al. (35) identified pitfalls in
the interpretation of IVUS images. Last, although IVUS
provides quantitative and qualitative information on coro-
nary artery lesions (36), no large study of its performance for
evaluating the LMCA has been reported to date. Our data
demonstrate the feasibility of stent-supported LMCA an-
gioplasty performed under angiographic guidance alone.
Use of IVUS for selecting the most appropriate stent or
improving stent apposition could be considered of addi-
Table 5. Factors Potentially Predictive of TLR Within Six
Months
TLR
n 5 20
No TLR
n 5 95
p
Value
Univariate Analysis
Age, yr (mean 6 SD) 64 6 10 70 6 10 0.016
Male gender (%) 17 78 NS
Unstable angina 9 49 NS
Diabetes mellitus 1 14 NS
Pressure 12.8 6 2.5 12.4 6 2.8 NS
Ref. diameter 3.59 6 0.67 3.67 6 0.6 NS
LVEF (%) 64.7 6 13 60.1 6 16 NS
Distal LM 11 50 NS
Multivariate Analysis
Age NS
LM 5 left main; LVEF 5 left ventricular ejection fraction; TLR 5 target lesion
revascularization.
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tional benefit only if it were shown to reduce the restenosis
rate, which is not the case for the time being.
Comparison with surgery. Only a randomized design
could provide a valid comparison of surgery versus stenting
in the treatment of LMCA stenosis. The undertaking of
such a study would require a large sample size and several
years of follow-up, but it may deserve to be considered in
view of the good results obtained in our group II patients,
who were good candidates for surgery. There is conclusive
evidence that surgery provides longer survival and greater
functional improvement than conservative therapy. How-
ever, the surgical mortality rate in the CASS registry was
4.6%, which is noticeably higher than the mortality rate in
our study. Also, the disadvantages of surgery are frequently
underestimated; they include a long hospital stay, delayed
wound healing, transfusion-related morbidity, restrictive
ventilatory defects, a need for a period of convalescence and
adverse consequences on work ability. Stenting shares the
well-known advantages of angioplasty, including an absence
of mortality in our study and in that by Park et al. (18) and
femoral hematoma as the only nonfatal complication. How-
ever, it also shares the main disadvantage of angioplasty,
namely a 23% overall risk of restenosis in our study.
However, stenting can be followed by surgery if needed and
obviates the need for surgery in most cases (82% in our
study).
Conclusions. Our data show that stent-supported angio-
plasty of the LMCA is feasible and is associated with
acceptable morbidity and mortality rates, particularly in
patients considered good candidates for surgery. It follows
that stent-supported angioplasty is a reasonable alternative
to CABG in the treatment of LMCA stenosis as long as the
operator is experienced in the technique and the risk of
restenosis is accepted.
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